CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 75-147

CHEMISTRY REVIEW(S)

Ē

- CHEMISTRY REVIEW NO. 2
- ANDA # 75-147 2.
- 3. NAME AND ADDRESS OF APPLICANT TEVA Pharmaceuticals USA Attention: Deborah A. Jaskot 650 Cathill Road Sellersville, PA 18960
- LEGAL BASIS FOR SUBMISSION The listed drug is Monoket® Tablets (Isosorbide Mononitrate) 20 mg of Schwarz Pharma.

The applicant certifies that to the best of their knowledge there are no listed patents and no listed exclusivities for Monoket® Tablets, 20 mg.

- 5. SUPPLEMENT(s): N/A
- 6. PROPRIETARY NAME: N/A
- 7. NONPROPRIETARY NAME: Isosorbide Mononitrate
- SUPPLEMENT(s) PROVIDE FOR: N/A 8.
- 9. AMENDMENTS AND OTHER DATES:

Firm:

Submitted: June 13, 1997

New Correspondence (Bio): August 15, 1997

Amendment: 12/17/97

Amendment: March 11, 1998 Subject of this review Telephone amendment: November 23, 1998

FDA:

Acknowledgement: July 29, 1997 Deficiency letter: January 21, 1998 Bioequivalency letter: January 11, 1998 Telephone Conversation: November 23, 1998

- ----

- 10. PHARMACOLOGICAL CATEGORY 11. Rx or OTC Vasodilator (Coronary) Rx
- 12. RELATED IND/NDA/DMF(s)


: = :

CHEMICAL NAME AND STRUCTURE

Isosorbide

 $C_6H_9NO_6$; M.W. = 191.14

Mononitrate



1,4:3,6-Dianhydro-D-glucitol 5-nitrate. CAS [16051-77-7]

16. RECORDS AND REPORTS: N/A

27

COMMENTS 17. Methods validation is requested on 10-5-98 and still pending Based on our telephone conversation on Nov-23-98, Teva Pharmaceuticals commits to fully cooperate with FDA disrict laboratories towards resolving any deficiencies or issues that may be brought forth during the review and validation of the test methods contained in this ANDA.

CONCLUSIONS AND RECOMMENDATIONS 18.

The application can be approved. The APPROVAL is pending for method validation.

19. REVIEWER: DATE COMPLETED: Sema Basaran, Ph.D.

October 9, 1998/11-23-98

Contain Trade Secret,

Commercial/Confidential

Information and are not
releasable.

chem Rev 2 10/9/90